Synopsis: Dr. Reddy’s Laboratories Limited is likely to remain in focus after Health Canada approved its generic semaglutide for weight loss, making it one of the first companies to receive approval for the drug in Canada. The approval strengthens the company’s presence in the rapidly growing global GLP-1 market for obesity treatment.
Shares of Dr. Reddy’s Laboratories Limited are likely to remain in focus after the company received approval from Health Canada for its generic version of semaglutide indicated for weight loss, marking a significant milestone in the global obesity drug market.
Dr. Reddy’s Laboratories Limited has a total market capitalization of approximately Rs. 1,12,372.40 crore. The company’s shares were trading at Rs. 1345.70 apiece on the stock exchange. The stock has declined 0.32 percent over the last five trading sessions and gained 4.29 percent over the last month. The stock touched a 52-week high of Rs. 1415 and a 52-week low of Rs. 1148.41.
Synopsis: Dr. Reddy’s Laboratories Limited is likely to remain in focus after Health Canada approved its generic semaglutide for weight loss, making it one of the first companies to receive approval for the drug in Canada. The approval strengthens the company’s presence in the rapidly growing global GLP-1 market for obesity treatment.
Shares of Dr. Reddy’s Laboratories Limited are likely to remain in focus after the company received approval from Health Canada for its generic version of semaglutide indicated for weight loss, marking a significant milestone in the global obesity drug market.
According to reports, Health Canada has approved generic semaglutide for weight management, making Canada the first G7 country to permit generic versions of the blockbuster GLP-1 therapy. Dr. Reddy’s Laboratories is among the companies that have secured approval, alongside Canadian pharmaceutical company Apotex. The approvals follow the expiry of key intellectual property protections, paving the way for generic competition in the Canadian market.
Semaglutide belongs to the GLP-1 receptor agonist class of medicines and is widely prescribed for obesity and Type 2 diabetes. The drug has witnessed unprecedented global demand due to its effectiveness in weight management and blood sugar control, making it one of the fastest-growing pharmaceutical segments worldwide. The entry of generic versions is expected to improve affordability while expanding patient access.
The approval strengthens Dr. Reddy’s presence in regulated international markets and aligns with its strategy of expanding its portfolio of complex generics and differentiated products. Successfully commercializing generic semaglutide could open a significant growth opportunity for the company, given the increasing demand for obesity therapies across developed markets.
The global obesity treatment market is expected to witness robust long-term growth, driven by rising obesity prevalence, growing healthcare awareness, and wider adoption of GLP-1 therapies. As patents on blockbuster drugs gradually expire, generic pharmaceutical companies with strong regulatory capabilities and manufacturing expertise are well positioned to capitalize on the emerging opportunity.
For investors, the approval highlights Dr. Reddy’s continued focus on high-value specialty generics and regulated markets. Expanding its portfolio in complex molecules such as semaglutide could strengthen international revenues, diversify its product mix, and reinforce its competitive position in the global pharmaceutical industry.
Incorporated in 1984, Dr. Reddy’s Laboratories Limited is a leading India-based pharmaceutical company engaged in the development, manufacturing, and marketing of generic medicines, active pharmaceutical ingredients (APIs), biosimilars, differentiated formulations, and custom pharmaceutical services. The company serves patients across more than 60 countries through a diversified portfolio spanning therapeutic segments including oncology, gastroenterology, cardiovascular, diabetes, and central nervous system disorders..
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of decisions based on this article. Please consult your investment advisor before investing.
